299 citations
,
March 2001 in “Journal of Investigative Dermatology” This study found that specific genetic markers near the androgen receptor gene are significantly more common in men with male pattern baldness, suggesting a genetic component in its development.
234 citations
,
February 2001 in “British Journal of Dermatology” FPHL affects hair density and diameter, causing visible hair loss in older women.
239 citations
,
November 2000 in “Journal of The American Academy of Dermatology” In this study, finasteride 1 mg/day for 12 months did not improve hair growth or slow hair thinning in postmenopausal women with androgenetic alopecia compared to placebo.
158 citations
,
February 2000 in “Archives of dermatology” This study reports that some patients with androgenetic alopecia may also exhibit clinical and histological features of inflammation and fibrosis, similar to those found in lichen planopilaris.
145 citations
,
December 1999 in “Journal of Investigative Dermatology Symposium Proceedings” Finasteride 1mg helps reverse hair miniaturization in men and postmenopausal women.
90 citations
,
January 1999 in “Journal of The American Academy of Dermatology” This article highlights a specific, yet largely unrecognized, sign that aids in diagnosing androgenetic alopecia in women, emphasizing its practical application in clinical settings.
581 citations
,
October 1998 in “Journal of The American Academy of Dermatology” In male pattern hair loss, this study found that finasteride 1 mg daily significantly slowed hair loss and increased hair growth over two years compared to placebo.
169 citations
,
June 1998 in “Journal of Investigative Dermatology” This study found no significant genetic association between the 5α-reductase enzyme genes and male pattern baldness, suggesting a polygenic etiology rather than simple inheritance.
76 citations
,
December 1997 in “Fertility and Sterility” This study found that spironolactone was significantly more effective than finasteride in reducing hirsutism scores over 9 months, despite more side effects occurring in the spironolactone group.
6 citations
,
December 1997 in “Journal of The American Academy of Dermatology” CTE can distort results in hair growth trials, so exclude it carefully.
416 citations
,
September 1997 in “Journal of Investigative Dermatology” People with hair loss have more androgen receptors and enzymes in certain follicles, with men and women showing different patterns.
75 citations
,
November 1996 in “Fertility and Sterility” This study found that finasteride effectively reduced hirsutism in women during 12 months of treatment, with some effects persisting in the majority after stopping the medication.
75 citations
,
October 1996 in “Dermatologic Clinics” This review examines chronic telogen effluvium, highlighting its distinctive features and the need for reassurance about its non-progressive nature, but reports no new clinical results.
24 citations
,
October 1994 in “Fertility and Sterility” This study suggests that in women with androgenic alopecia and men with premature balding, enhanced 5α-reductase activity and altered androgen conjugation, favoring sulfurylation, may be involved in scalp hair loss.
325 citations
,
June 1994 in “Archives of Dermatology” This study observed that progressive frontal recession in postmenopausal women may exhibit features of fibrosing alopecia, suggesting a distinct reaction pattern from typical lichen planopilaris.
82 citations
,
March 1994 in “Archives of Dermatology” This study found that a 2% topical minoxidil solution significantly increased hair regrowth compared to placebo in women with androgenetic alopecia over 32 weeks.
165 citations
,
February 1994 in “Fertility and Sterility” This study found that flutamide was more effective than spironolactone in reducing symptoms of hirsutism and related conditions in premenopausal women, with fewer discontinuations due to side effects.
309 citations
,
May 1993 in “Journal of The American Academy of Dermatology” This study concluded that horizontal sections of scalp biopsy specimens provide more diagnostic information for male pattern androgenetic alopecia than vertical sections and can predict hair regrowth potential following topical minoxidil therapy.
83 citations
,
April 1992 in “Clinical Endocrinology” This study found that treatment with cyproterone acetate and ethinyl oestradiol increased hair density in women with diffuse androgen-dependent alopecia, particularly when serum ferritin levels were above 40 μg/l.
32 citations
,
January 1990 in “Clinical Endocrinology” This study found that women with female pattern androgenic alopecia have significantly higher levels of certain androgens and androgen sulfates compared to normal premenopausal women, suggesting markers for diagnosis and treatment efficacy.
121 citations
,
March 1989 in “Journal of Investigative Dermatology” Minoxidil can help grow hair in mice by making cells grow and improving hair quality. More research needed.
130 citations
,
May 1988 in “Journal of The American Academy of Dermatology” This study found that frontal and frontoparietal hair recession is relatively common in women, especially after menopause, and may not indicate abnormal androgen metabolism absent other virilization signs.
52 citations
,
March 1987 in “Journal of the American Academy of Dermatology” This study found that men with rapidly progressive male pattern baldness had elevated serum dehydroepiandrosterone sulfate levels, suggesting that adrenal hyperactivity may contribute to alopecia in genetically susceptible young men.
14 citations
,
September 1986 in “Archives of Dermatology” This study found that women with female pattern baldness had a marked increase in the 3α,17β-androstanediol glucuronide/sex hormone binding globulin ratio and low serum sex hormone binding globulin.
138 citations
,
August 1985 in “Journal of The American Academy of Dermatology” Minoxidil promotes hair growth in male pattern baldness.
101 citations
,
January 1985 in “British Journal of Dermatology” This article discusses oral spironolactone therapy for female patients with acne, hirsutism, or androgenic alopecia and reports no new clinical results.
203 citations
,
November 1984 in “Journal of the American Academy of Dermatology” This study presents evidence suggesting that androgenetic alopecia is most likely inherited through a polygenic model, challenging the traditional view that it is caused by a simple Mendelian autosomal dominant gene.
46 citations
,
June 1983 in “Cleveland Clinic Journal of Medicine” In this study, women with diffuse alopecia were found to have higher serum levels of adrenal androgen DHEAS, which may contribute to disrupted scalp hair growth.
24 citations
,
May 1982 in “Biochemical Pharmacology” These drugs cause hair growth without affecting testosterone or adrenal hormones.
40 citations
,
March 1982 in “British Journal of Dermatology” This study found that women experiencing diffuse hair loss had significantly lower levels of plasma sex-hormone binding globulin compared to controls, while their testosterone levels remained normal.
666 citations
,
September 1977 in “British Journal of Dermatology” This article presents a classification system for stages of female-pattern androgenetic alopecia to aid early diagnosis and mentions existing systems for rare male-pattern cases, but reports no new clinical results.
63 citations
,
October 1972 in “British Journal of Dermatology” Women with thinning hair have thinner hair strands than women without hair loss.
